Recruiting
Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
To compare the efficacy and tolerability of Electroconvulsive Therapy (ECT) and Magnetic Seizure Therapy (MST) in patients with major depressive disorder (MDD).
ClinicalTrials.gov IDNCT07473648
PhaseNA
Enrollment200
SponsorThe Second Hospital of Anhui Medical University
Age12 Years
SexALL
Conditions studied
Electroconvulsive Therapy, Major Depressive Disorder, Magnetic Seizure Therapy
About this study
To compare the efficacy and tolerability of Electroconvulsive Therapy (ECT) and Magnetic Seizure Therapy (MST) in patients with major depressive disorder (MDD).
Interventions
- Device: Electroconvulsive Therapy — Electroconvulsive therapy will be administered two to four times a week according to a standardized protocol. Stimulation parameters (including intensity, target location, session number, and duration) will be individualized for each participant based on prior research to ensure targeted and safe delivery within established safety limits. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.
- Device: Magnetic Seizure Therapy — Magnetic seizure therapy will be administered two to four times a week according to a standardized protocol. Stimulation parameters (including intensity, target location, session number, and duration) will be individualized for each participant based on prior research to ensure targeted and safe delivery within established safety limits. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.
Primary outcomes
- Change in Hamilton Depression Rating Scale Total Score. (Baseline, immediately after each treatment session during the intervention period, and 6 months after the end of intervention.)
- Change in heart rate variability (HRV) parameters derived from electrocardiogram (ECG). (Baseline, immediately after each treatment session during the intervention period, and 6 months after the end of intervention.)
- Change in Hamilton Anxiety Rating Scale Total Score. (Baseline, immediately after each treatment session during the intervention period, and 6 months after the end of intervention.)
- Change in the Overall Composite Score of the MATRICS Consensus Cognitive Battery. (Baseline and after the completion of the last session (an average of 2 weeks).)
Eligibility information
Inclusion Criteria:
* Aged 12-80 years;
* Diagnosis confirmed by two psychiatrists per DSM-5;
* Stable medication regimen pre-enrollment;
* Indicated for neuromodulation OR with visual field defects.
Exclusion Criteria:
* Major systemic diseases;
* Prior neuromodulation within 3 months;
* Pregnancy or potential pregnancy;
* Metal implants or claustrophobia.
Study locations
- Anhui Medical University, Hefei, Anhui China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.